• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term efficacy and improved overall survival of lorlatinib in anaplastic lymphoma kinase-rearranged lung cancer: is cure a dream or a reality?

作者信息

Horio Yoshitsugu, Kuroda Hiroaki, Sasaki Eiichi, Masago Katsuhiro

机构信息

Department of Outpatient Services, Aichi Cancer Center Hospital, Nagoya, Japan.

Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

出版信息

Transl Lung Cancer Res. 2025 Jun 30;14(6):2353-2358. doi: 10.21037/tlcr-2025-694. Epub 2025 Jun 26.

DOI:10.21037/tlcr-2025-694
PMID:40673079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12261235/
Abstract
摘要

相似文献

1
Long-term efficacy and improved overall survival of lorlatinib in anaplastic lymphoma kinase-rearranged lung cancer: is cure a dream or a reality?劳拉替尼治疗间变性淋巴瘤激酶重排肺癌的长期疗效及总生存期改善：治愈是梦想还是现实？
Transl Lung Cancer Res. 2025 Jun 30;14(6):2353-2358. doi: 10.21037/tlcr-2025-694. Epub 2025 Jun 26.
2
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶（<I>ALK</I>）重排非小细胞肺癌的靶向治疗。
Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.
3
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.一线治疗晚期间变性淋巴瘤激酶突变型非小细胞肺癌患者的疗效和安全性：系统评价和网络荟萃分析。
Cancer. 2023 Apr 15;129(8):1261-1275. doi: 10.1002/cncr.34664. Epub 2023 Feb 7.
4
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.关键2期研究中劳拉替尼治疗ALK阳性非小细胞肺癌患者的最终总生存期和长期安全性：简要报告
J Thorac Oncol. 2025 Apr;20(4):513-520. doi: 10.1016/j.jtho.2024.11.021. Epub 2024 Nov 22.
5
Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR.抗表皮生长因子受体（EGFR）疗法可克服因EGFR激活介导的对第三代间变性淋巴瘤激酶（ALK）-酪氨酸激酶抑制剂劳拉替尼的获得性耐药。
Acta Pharmacol Sin. 2025 Mar 21. doi: 10.1038/s41401-025-01511-z.
6
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).洛拉替尼与其他间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKI）作为一线治疗ALK 阳性晚期非小细胞肺癌（NSCLC）的比较：系统评价和网络荟萃分析。
Lung Cancer. 2024 Nov;197:107968. doi: 10.1016/j.lungcan.2024.107968. Epub 2024 Sep 29.
7
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.比较伴有 ALK 重排的晚期非小细胞肺癌一线治疗的疗效和安全性：临床试验的荟萃分析。
BMC Cancer. 2021 Nov 26;21(1):1278. doi: 10.1186/s12885-021-08977-0.
8
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.洛拉替尼治疗既往治疗的间变性淋巴瘤激酶重排的非小细胞肺癌：全球研究的日本亚组分析。
Cancer Sci. 2020 Oct;111(10):3726-3738. doi: 10.1111/cas.14576. Epub 2020 Sep 11.
9
Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.动态监测循环肿瘤 DNA 分析 ALK 阳性经治 NSCLC 患者中 lorlatinib 的遗传特征和耐药谱。
Thorac Cancer. 2023 Jul;14(20):1980-1990. doi: 10.1111/1759-7714.14980. Epub 2023 Jun 2.
10
Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.劳拉替尼、阿来替尼和布加替尼在初治/未治疗的ALK阳性晚期非小细胞肺癌中的比较：一项系统评价和网状Meta分析
J Chemother. 2022 Apr;34(2):87-96. doi: 10.1080/1120009X.2021.1937782. Epub 2021 Jun 17.

本文引用的文献

1
Neoadjuvant Osimertinib for Resectable -Mutated Non-Small Cell Lung Cancer.新辅助奥希替尼用于可切除的表皮生长因子受体（EGFR）突变型非小细胞肺癌
J Clin Oncol. 2025 Jun 2:JCO2500883. doi: 10.1200/JCO-25-00883.
2
Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring.用于癌症特征分析、残留疾病检测和治疗监测的液体活检方法。
Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e481114. doi: 10.1200/EDBK-25-481114. Epub 2025 Apr 30.
3
ALK in cancer: from function to therapeutic targeting.癌症中的间变性淋巴瘤激酶：从功能到治疗靶点
Nat Rev Cancer. 2025 May;25(5):359-378. doi: 10.1038/s41568-025-00797-9. Epub 2025 Mar 7.
4
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.关键2期研究中劳拉替尼治疗ALK阳性非小细胞肺癌患者的最终总生存期和长期安全性：简要报告
J Thorac Oncol. 2025 Apr;20(4):513-520. doi: 10.1016/j.jtho.2024.11.021. Epub 2024 Nov 22.
5
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.NVL-655是一种对多种ALK突变癌蛋白具有选择性且能穿透血脑屏障的抑制剂，包括对劳拉替尼耐药的复合突变。
Cancer Discov. 2024 Dec 2;14(12):2367-2386. doi: 10.1158/2159-8290.CD-24-0231.
6
Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies.肿瘤细胞耐药性休眠细胞的可塑性：提高抗癌疗法效果的革新策略。
Signal Transduct Target Ther. 2024 Aug 14;9(1):209. doi: 10.1038/s41392-024-01891-4.
7
Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges.阿来替尼用于早期间变性淋巴瘤激酶阳性非小细胞肺癌：当前证据与未来挑战
Cancers (Basel). 2024 Jul 22;16(14):2610. doi: 10.3390/cancers16142610.
8
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies.癌症中的ALK抑制剂：耐药机制与治疗管理策略
Cancer Drug Resist. 2024 May 23;7:20. doi: 10.20517/cdr.2024.25. eCollection 2024.
9
Lorlatinib Versus Crizotinib in Patients With Advanced -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.洛拉替尼对比克唑替尼用于治疗晚期 ALK 阳性非小细胞肺癌患者：III 期 CROWN 研究的 5 年结果。
J Clin Oncol. 2024 Oct 10;42(29):3400-3409. doi: 10.1200/JCO.24.00581. Epub 2024 May 31.
10
Overcoming Central β-Sheet #6 (Cβ6) Mutation (L1256F), Mutations and Short Forms of and Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.克服中央β-折叠#6（Cβ6）突变（L1256F）、突变以及短形式和剪接变体是重新构想的第五代（5G）ALK酪氨酸激酶抑制剂必须满足的未被满足的需求。
Lung Cancer (Auckl). 2024 Feb 27;15:19-27. doi: 10.2147/LCTT.S446878. eCollection 2024.